Topical Sevoflurane for Treatment of Chronic Leg Ulcers
Analgesic and Healing Effect of Topical Sevoflurane for Chronic Venous Ulcers
Charles University, Czech Republic
50 participants
May 2, 2022
INTERVENTIONAL
Conditions
Summary
Patients with painful non-healing leg ulcer will be enrolled in the clinical single-blinded randomized study. The active treatment group will have sevoflurane applied at approximately 1 ml/cm2 at the start of wound treatment, the control group will only have a standard rinse solution with Cyteal TM (Pierre Fabre Medicament, France). Further treatment will then be carried out in the standard manner. The duration of the study will be 5 days; if the defect heals earlier, it will be terminated early. Exclusion criteria: allergy to sevoflurane, inability to understand the questionnaire Parameters to be monitored will be pain intensity, microbial colonization, appearance and size of the defect
Eligibility
Inclusion Criteria1
- Patients with painful (pain intensity on the numerical scale NRS 0-10 is NRS>4) non- healing tibial venous ulcers
Exclusion Criteria2
- Allergy to sevoflurane
- Inability to understand the pain-intensity questionnaire
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Topical application of 1 mL sevoflurane per 1 cm2 ulcer area once or two times daily.
Rinsing and cleaning of ulcer.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05303805